Unlike studies undertaken by Masaki et al. and Attramadal et al., our study showed that CD44 expression in tumor buds was significantly lower than that in the main tumor body (16.1% vs. 65.5%), which was not consistent with our expected results. The gene discussed is CD44; the disease is neoplasm.